(Q34413316)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Denis Mulleman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jean-Camille Méric

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Emilie Ducourau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Charlotte Magdelaine-Beuzelin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jean-Pierre Valat

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Philippe Goupille

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Centre National de la Recherche Scientifique UMR 6239 GICC

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

25 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

Arthritis Research and Therapy

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

R178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1186/ar2867

12 February 2020

exact match

0 references

cites work

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Infliximab pharmacokinetics in inflammatory bowel disease patients.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003525

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease

9 December 2018

1 reference

12 December 2020

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study

1 reference

12 December 2020

Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study

1 reference

12 December 2020

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

12 December 2020

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

12 December 2020

A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy

1 reference

12 December 2020

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1186/AR2867

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19939280%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

19939280

1 reference